Abridge has raised $1B across 2 funding rounds, plus 2 undated rounds. The latest round valued Abridge at $5.3B post-money, with Andreessen Horowitz, Khosla Ventures on the lead line.
Abridge Emerges as a Healthcare AI Leader, Raising $150M, in a round it closed in February 2024 that it said reflected enterprise-grade demand for its EMR-integrated documentation technology.
2 funding rounds, the latest highlighted.
Abridge was founded in 2018, United States.
No date is disclosed for this round.
A primary round — the company sells new shares to investors it selects. $250M raised, led by Elad Gil, IVP.
A primary round — the company sells new shares to investors it selects. $316M raised, led by Andreessen Horowitz, Khosla Ventures.
No filing has been made.
2 dated rounds, newest first.
Lightspeed Venture PartnersLEAD
Andreessen HorowitzLEAD
Khosla VenturesLEADEElad GilLEAD
IVPLEAD
Redpoint Ventures
Spark Capital
Union Square Ventures
Bessemer Venture PartnersWWittington VenturesKKaiser Permanente Ventures
CVS Health VenturesThe closest healthcare technology and ai (ai-powered clinical documentation) peers are on the competitors page.
The routes section explains what is realistically available for a company at this stage.
No. Abridge is a private company; its shares do not trade on a public exchange.
The last valuation is $5.3B (post-money, Apr 2026).
Perpetual markets for stocks, gold, indices and pre-IPO names — settled on-chain, no wallet-to-exchange transfers.
